Keyword: Boston Scientific
Manufacturers including Abbott, Boston Scientific and Medtronic have argued that the ceiling makes their high-end products commercially unviable.
Boston Scientific released its full-year earnings forecast that fell below Wall Street expectations as the company reiterated its plans to make several more acquisitions in the coming year.
The agreement sees Boston Scientific buy $90 million of Millipede stock and gain the right to acquire the rest of the business for up to $450 million.
Official statistics show a 59% year-on-year drop in foreign direct investment over the first nine months of 2017.
The FDA gave the green light to Boston Scientific’s first-of-its-kind electric pulse system designed to treat pain without the use of opioids.
Boston Scientific said it was delaying the commercial release in the U.S. and Europe of its Lotus Edge aortic valve system.
The FDA is considering alternative options, such as importing medical devices, to handle a potential device shortage.
Boston Scientific forked over $175 million up front for Apama Medical, which is working on a new treatment for afib.
Here is Monday's medtech news of note.
The FDA cleared Medtronic's latest spinal cord stimulation system for the treatment of chronic intractable pain.